DISCOvERIE Project

DISCOvERIE project will determine mechanisms of intestinal and central nervous system function underlying comorbidities in IBS and their interaction with the peripheral microbiota-gut-brain axis. The 5-years project (2020-2025) will identify biomarkers for more accurate and earlier diagnosis, prognosis and monitoring of patients’ condition. This pioneer project is financed by European Commission’s H2020 Research Fund. The DISCOvERIE public private project was set up under the framework of Horizon2020 is coordinated by Dr Javier Santos, Gastroenterology Department of Vall d’Hebron University Hospital and principal investigator at the Physiology and Pathophysiology of the Digestive Tract research group of the Vall d’Hebron Research Institute (VHIR); and Dr Josep Antoni Ramos-Quiroga, head of the Psychiatric Department of Vall d’Hebron University Hospital and principal investigator of the Psychiatry, Mental Health and Addictions research group at the VHIR. The DISCOvERIE consortium represents a renowned group of clinical and research experts and opinion leaders in the field of neuro-gastroenterology, psychiatric disorders and somatic pain disorders. It is integrated by universitary hospitals and third parties across Europe:Vall d’Hebron Research Institute, Spain; Goeteborgs Universitet, Sweden; Johann Wolfgang Goethe-Universitat Frankfurt Am Main and Universitaetsklinikum Heidelberg, Germany; Alma Mater Studiorum – Universita di Bologna, Italy; Semmelweis Egyetem, Hungary; Katholieke Universiteit Leuve KU Leuven and VIB, Belgium; Universitatea De Medicina Si Farmacie Iuliu Hatieganu, Romania; Stichting Katholieke Universiteit and Universiteit Maastricht, Netherlands; and University College Cork – National University of Ireland, Ireland.The SMEs in Spain are Anaxomics Biotech, Byte Factory, HumanITcare, and Cliclab; in Austria is Emergentec Biodevelopment Gmbh; in Netherlands, Hycult Biotech and in USA, Nanostring Technologies Inc.